<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01845493</url>
  </required_header>
  <id_info>
    <org_study_id>13-0056</org_study_id>
    <nct_id>NCT01845493</nct_id>
  </id_info>
  <brief_title>Sulforaphane Supplementation in Atopic Asthmatics</brief_title>
  <acronym>brasma</acronym>
  <official_title>Sulforaphane Supplementation in Atopic Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will perform a pilot study of daily treatment with oral sulforaphane (SFN)&#xD;
      for 3 days to determine if Nuclear factor (erythroid-derived 2)-like 2 (NRF2) induction is&#xD;
      possible with this supplementation regimen in individuals with allergic asthma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot study will examine if oral SFN supplementation can induce NRF2 and NRF2-dependent&#xD;
      phase II enzymes in nasal epithelial cells of allergic asthmatics. Subjects will receive both&#xD;
      a SFN-rich broccosprout homogenate preparation and an alfalfa sprout homogenate (placebo) in&#xD;
      a crossover fashion. mRNA levels of NRF2 and NRF2-dependent phase II enzymes will be compared&#xD;
      between the active and placebo periods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mRNA levels of NRF2 and NRF2-dependent phase II enzymes in nasal epithelial cells</measure>
    <time_frame>2 hours post third ingestion of SFN/placebo ingestion</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Sulforaphane-rich supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: broccosprout homogenate (rich in Sulforaphane) taken orally daily x 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alfalfa Sprout Homogenate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: Alfalfa sprout homogenate taken daily x 3 days (poor in sulforaphane)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Alpha Sprout Homogenate</intervention_name>
    <description>Alpha Sprout Homogenate</description>
    <arm_group_label>Alfalfa Sprout Homogenate</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sulforaphane Homogenate</intervention_name>
    <description>Active</description>
    <arm_group_label>Sulforaphane-rich supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-50 of both genders&#xD;
&#xD;
          2. History of episodic wheezing, chest tightness, or shortness of breath after age of 6&#xD;
             years consistent with asthma, or physician diagnosed asthma after age of 6 years.&#xD;
&#xD;
          3. AND: Positive methacholine test. A positive test is defined as a provocative&#xD;
             concentration of methacholine of 10 mg/ml or less producing a 20% fall in FEV1 (PC20&#xD;
             methacholine). Methacholine challenge in a separate screening protocol (98-0799), or&#xD;
             from other venues will be accepted.&#xD;
&#xD;
          4. OR: Pre and post bronchodilator FEV1 improvement by 12% or more after 4 puffs of&#xD;
             albuterol inhaler.&#xD;
&#xD;
          5. FEV1 of at least 80% of predicted and FEV1/FVC ratio of at least .70 (without use of&#xD;
             bronchodilating medications for 12 hours), consistent with lung function of persons&#xD;
             with no more than mild episodic or mild persistent asthma (NHANES III predicted set).&#xD;
&#xD;
          6. Allergic sensitization to at least one of the following allergen preparations: (House&#xD;
             Dust Mite f, House dust mite p, Cockroach, Tree mix, Grass Mix, Weed Mix, Mold Mix 1,&#xD;
             Mold Mix 2, Rat, Mouse, Guinea Pig, Rabbit, Cat or Dog) confirmed by positive&#xD;
             immediate skin test response in a separate screening protocol. Proof of allergy from&#xD;
             other venues, including ImmunoCAP testing from a medical workup, provided by the&#xD;
             subject, will be accepted.&#xD;
&#xD;
          7. Oxygen saturation of &gt; 94 % and normal blood pressure (Systolic between 150 - 90,&#xD;
             Diastolic between 90-60 mm Hg)&#xD;
&#xD;
          8. Willing to provide information regarding health history and habits of cigarette smoke&#xD;
             exposure;&#xD;
&#xD;
          9. Willing to avoid antioxidant vitamins and cruciferous vegetables as well as&#xD;
             juices/drinks with added vitamin supplements for 2 days prior the baseline screening&#xD;
             visit and throughout initial dosing period.&#xD;
&#xD;
         10. Subjects must be willing to avoid antihistamine use for 4 days prior to each session&#xD;
             and NSAIDs for 7 days prior to each session. Nasal steroids must be held for 2 weeks&#xD;
             prior to the session.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Medical history or underlying health problems that preclude participation in the&#xD;
             protocol per the study physician;&#xD;
&#xD;
          2. Current nutritional disorder such as anorexia, bulimia, irritable bowel syndrome,&#xD;
             Crohn's disease etc;&#xD;
&#xD;
          3. Use of oral corticosteroids within the past 4 weeks;&#xD;
&#xD;
          4. Presence of upper or lower respiratory tract infection or treatment with antibiotics&#xD;
             within the previous 4 weeks;&#xD;
&#xD;
          5. Pregnancy as determined by menstrual history or urine pregnancy test;&#xD;
&#xD;
          6. Current smokers will be excluded. Anyone with a smoking history &gt; 0.5 pack year and/or&#xD;
             &gt;1 pack per month will also be excluded.&#xD;
&#xD;
          7. History of bleeding disorder;&#xD;
&#xD;
          8. Recent nasal surgery (with 6 months). If a subject has had nasal surgery between 6&#xD;
             months and 5 years, a study physician will visualize the area prior to the biopsy to&#xD;
             evaluate the suitability of the nose for the procedure.&#xD;
&#xD;
          9. History of intolerance of or aversion to broccoli&#xD;
&#xD;
         10. Unable to withhold nasal steroids for 2 weeks before each session. These subjects may&#xD;
             be deferred until after their allergy season.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle L Hernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>center for environmental medicine asthma and lung biology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Environmental Protection Agency at the University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>April 17, 2013</study_first_submitted>
  <study_first_submitted_qc>April 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2013</study_first_posted>
  <last_update_submitted>March 7, 2016</last_update_submitted>
  <last_update_submitted_qc>March 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Michelle Hernandez, MD</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>Asthmatics</keyword>
  <keyword>allergic</keyword>
  <keyword>allergies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulforaphane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

